-+ 0.00%
-+ 0.00%
-+ 0.00%

CG Oncology stock trades up, here is why

Barchart·11/16/2026 08:26:13
Listen to the news

CGON Cover Image

What happened?

Shares of CG Oncology jumped 31.3% in the pre-market session after the company announced positive topline results from PIVOT-006, its Phase 3 registrational trial evaluating adjuvant intravesical cretostimogene grenadenorepvec in patients with NMIBC. According to the company's press release, the trial evaluated the therapy following complete tumor resection in patients with intermediate-risk and high-grade Ta ≤3 cm NMIBC. The company stated that there are currently no U.S. FDA approved adjuvant treatment options in this patient population of approximately 50,000 patients.

What is the market telling us

CG Oncology’s shares are very volatile and have had 23 moves greater than 5% over the last year. But moves this big are rare even for CG Oncology and indicate this news significantly impacted the market’s perception of the business.

CG Oncology is up 135% since the beginning of the year, and at $98.26 per share, it has set a new 52-week high. Investors who bought $1,000 worth of CG Oncology’s shares at the IPO in January 2024 would now be looking at an investment worth $2,645.

ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.

Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.